July 1, 2026: MDL About Wegovy and Other GLP-1 Medications Gains Momentum There are now about 3,848 lawsuits that have been consolidated in the MDL about whether Wegovy and similar GLP-1 products caused unexpected complications
USA 105 , 1437114376 (2008)
This self-injected drug promises to treat Type 2 diabetes and, to some extent, promote weight loss
CrossRefDirect Link Aebi, H., 1984
It is also indicated together with diet and exercise to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI 27 kg/m)
Patients typically begin on a lower introductory dose to allow the body to adjust comfortably, which our Allen-based providers then gradually increase over time based on your individual progress and tolerance